Skip Navigation



Glycobiology Advance Access published online on June 8, 2009
Glycobiology, doi:10.1093/glycob/cwp080
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow All Versions of this Article:
19/9/1002    most recent
cwp080v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Akeboshi, H.
Right arrow Articles by Jigami, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akeboshi, H.
Right arrow Articles by Jigami, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Production of human β-hexosaminidase A with highly phosphorylated N-glycans by the overexpression of Ogataea minuta MNN4 gene

Hiromi Akeboshi1,2, Yoshiko Kasahara1,2, Daisuke Tsuji2,3, Kohji Itoh2,3, Hitoshi Sakuraba2,4, Yasunori Chiba1,2* and Yoshifumi Jigami1,2*

1 Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba 305-8566, Japan
2 CREST, JST, Kawaguchi 332-0012, Japan
3 Department of Medicinal Biotechnology, Institute for Medicinal Resources, Graduate School of Pharmaceutical Sciences, The University of Tokushima, Tokushima 770-8505, Japan
4 Department of Analytical Biochemistry, Meiji Pharmaceutical University, Tokyo 204-8588, Japan

* Addresses correspondence to: Yasunori Chiba, Research Center for Medical Glycoscience, AIST Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan. Tel: +81-29-861-6082; Fax: +81-29-861-6083; E-Mail: y-chiba{at}aist.go.jp; and Yoshifumi Jigami, Research Center for Medical Glycoscience, AIST Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan. Tel: +81-29-861-6160; Fax: +81-29-861-6161; E-Mail: jigami.yoshi{at}aist.go.jp

Received on February 25, 2009; accepted on June 3, 2009

Effective enzyme replacement therapy for lysosomal storage diseases requires a recombinant enzyme with highly phosphorylated N-glycans. Recombinant human β-hexosaminidase A is a potentially therapeutic enzyme for GM2-gangliosidosis. Recombinant HexA has been produced by using the methylotrophic yeast Ogataea minuta as a host, and the purified enzyme was tested for its replacement effect on cultured fibroblasts derived from GM2-gangliosidosis patients. Although therapeutic effect was observed, in order to obtain higher therapeutic effect with little dose as possible, increased phosphorylation of recombinant β-hexosaminidase A N-glycans is suggested to be prerequisite. In the budding yeast Saccharomyces cerevisiae, overexpression of MNN4, which encodes a positive regulator of mannosylphosphate transferase, led to increased mannosylphosphate contents. In the present study, we cloned OmMNN4, a homologous gene to ScMNN4, based on the genomic sequence of O. minuta. We overexpressed the cloned gene under the control of the alcohol oxidase promoter in a β-hexosaminidase A-producing yeast strain. Structural analysis of pyridylamine-labeled N-glycans by high-performance liquid chromatography revealed that overexpression of MNN4 caused a three-fold increase in phosphorylated N-glycans of recombinant β-hexosaminidase A. Recombinant enzyme prepared from strains overexpressing OmMNN4 was more effectively incorporated into cultured fibroblasts and neural cells, and it more rapidly degraded the accumulated GM2-ganglioside as compared to the control enzyme. These results suggest that β-hexosaminidase A produced in a strain that overexpresses OmMNN4 will act as an effective enzyme for use in replacement therapy of GM2-gangliosidosis.

Key words: Enzyme replacement therapy / GM2-gangliosidosis / β-Hexosaminidase A / Methylotrophic yeast / MNN4


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.